Intravitreal Ranibizumab and Bevacizumab: A Review of Risk

Author： Dafer Rima   Schneck Michael   Friberg Thomas   Jay Walter  

Publisher： Informa Healthcare

ISSN： 0882-0538

Source： Seminars in Ophthalmology, Vol.22, Iss.3, 2007-07, pp. : 201-204

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Large Subretinal Haemorrhage following Change from Intravitreal Bevacizumab to Ranibizumab

By  

Ophthalmologica, Vol. 223, Iss. 4, 2009-04 ,pp. : 279-282

Karger

Access to resources Recommend Favorite

The Effectiveness of Intravitreal Ranibizumab in Patients with Diabetic Macular Edema Who Have Failed to Respond to Intravitreal Bevacizumab

By  

Ophthalmologica, Vol. 235, Iss. 3, 2016-03 ,pp. : 133-136

Karger

Access to resources Recommend Favorite

Intravitreal Ranibizumab and Bevacizumab in Combination with Full-Fluence Verteporfin Therapy and Dexamethasone for Exudative Age-Related Macular Degeneration

By  

Ophthalmic Research, Vol. 45, Iss. 3, 2010-09 ,pp. : 129-134

Karger

Access to resources Recommend Favorite

Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration

By  

Ophthalmologica, Vol. 223, Iss. 6, 2009-07 ,pp. : 370-375

Karger

Access to resources Recommend Favorite

Arterial Thromboembolic Events in Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Bevacizumab or Ranibizumab

By  

Ophthalmologica, Vol. 225, Iss. 4, 2011-02 ,pp. : 211-221

Karger

Access to resources Recommend Favorite